Abstract: An antibody-drug conjugate, and a preparation method therefor and a use thereof are provided. A hydrophilic linker in the conjugate can satisfy linking of most active molecules. Moreover, the antibody-drug conjugate has good stability, hydrophilicity, and pharmacokinetic properties. The antibody-drug conjugate can be used in pharmaceutical compositions and can b used in treating cancers.

Abstract: A pharmaceutical composition comprising an antibody-drug conjugate, a preparation method therefor and a use thereof. Specifically, provided are a pharmaceutical composition comprising an antibody-drug conjugate represented by formula I, which is an injection, a preparation method therefor, and a use thereof in the preparation for a drug for treating proliferative diseases.

Abstract: Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.

Abstract: The present application provides an anti-CLDN18.2 antibody and an antibody-drug conjugate prepared from the antibody. The antibody or the antibody-drug conjugate can effectively treat CLDN18.2 positive tumors, comprising but not limited to cancers represented by gastric cancer and pancreatic cancer.

Abstract: A pharmaceutical composition includes an antibody-drug conjugate, a histidine buffer, trehalose, and a surfactant. A method for preparing the pharmaceutical composition is also provided. For example, the antibody-drug conjugate is formed by conjugating a drug-linker to an anti-Nectin-4 monoclonal antibody. In addition, the antibody may include a heavy chain and a light chain. The heavy chain may have three CDR regions having amino acid sequences set forth in SEQ ID NOs: 1, 2 and 3, respectively. The light chain may have three CDR regions having amino acid sequences set forth in SEQ ID NOs: 4, 5 and 6, respectively.

Abstract: A pharmaceutical composition is provided, including a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor (EGFR) inhibitor. The pharmaceutical composition can be used to treat various cancers, including solid tumors. The combination product can be used to treat any number of diseases related to PRMT5 and/or EGFR.

Abstract: A pharmaceutical composition is provided, including a pharmaceutical composition or a combined pharmaceutical composition of a protein arginine methyltransferase 5 (PRMT5) inhibitor and a PD-1/PD-L1 inhibitor. The PD-1/PD-L1 inhibitor is a small molecule compound, nucleic acid, peptide, protein, antibody, peptide antibody, double antibody, mini antibody, single chain fragment variable or a fragment or variant or any combination thereof. The pharmaceutical composition can be used to treat various cancers, including solid tumors.

Abstract: A novel anti-CD73 antibody and use thereof are provided. The anti-CD73 antibody can be used for treating tumors, particularly tumors expressing CD73 (CD73+) on the surface of tumor cells.

Abstract: Novel compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity, as well as method for their preparation and use are provided. Specifically, compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates, as well as method for their preparation and use are provided. Where, W is C; X3 is N or CRX3; X4 is N or CRX4; X5 is N or CRX5; X6 is N or CRX6.

Abstract: Disclosed are an anti-human PVRIG antibody or an antigen-binding fragment thereof, as well as an application thereof in the preparation of a medicament for treating diseases, such as cancer, which are related to the abnormal expression of PVRIG.

Abstract: An antibody-drug conjugate targeting HER2, HER3 and EGFR, and a pharmaceutically acceptable salt, a hydrate, a solvate or an isotopically labelled analogue thereof, the use thereof, and a preparation method therefor.

Abstract: The present application provides a pharmaceutical composition, comprising an anti-CLDN18.2 antibody-drug conjugate, a buffer, a stabilizer and a surfactant. The present application further provides a method for preparing the pharmaceutical composition and use of the pharmaceutical composition.

Abstract: Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.

Abstract: Described herein are crystalline forms of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof. Also described herein are pharmaceutical formulations of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof.

Abstract: A leak-proof atomizing component, which comprises an atomizing head and a atomizing core; The atomizing head is provided with a liquid return hole that is connected with the peripheral bottle body; When the return liquid hole is only one, the diameter of the return liquid hole is the first preset value, so that the liquid in the peripheral bottle cannot continuously flow out from the return liquid hole when the peripheral bottle is poured; When the return liquid hole is multiple, the diameter of the return liquid hole is the second preset value, so that when the peripheral bottle body is poured, the liquid in the peripheral bottle body cannot continuously flow out of the return liquid hole due to the existence of liquid tension. By optimizing the return hole, the component avoids continuous liquid out flow through the return hole when the bottle is poured.